Trial Profile

Study of ATA3431

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATA 3431 (Primary)
Indications B-cell lymphoma
Focus Adverse reactions

Most Recent Events

09 May 2024 According to an Atara Biotherapeutics media release, company is progressing toward an IND submission in H2 2025
10 Jan 2024 New trial record
08 Jan 2024 According to an Atara Biotherapeutics media release, the company is advancing ATA3431 into IND-enabling studies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com